Carnosine for Peripheral Arterial Disease Patients

Part of paid clinical trials in Louisville, Kentucky.

Sponsor
Shahid Baba
Study ID
NCT05371145
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Peripheral Arterial Disease

Eligibility Criteria

Sex
MALE
Age
50 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Carnosine — BIOLOGICAL
    Determine whether carnosine supplementation (2 g/day) for 3 months in peripheral arterial disease patients improves 6MWT ability.

Study Details

Oral supplementation of L-carnosine will increase muscle carnosine, stabilize HIF1-alpha promote angiogenesis, and thus improve the functioning of lower extremities in PAD patients.

Key Dates

Start date
Mar 1, 2023
Status verified
Jul 2024
Primary completion
Dec 30, 2024
Completion
Dec 30, 2024

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Carnosine intervention for patients with PAD
    This is a single arm open labelled safety trial, where we will supplement carnosine for 3 months to subjects with non-claudication and claudication peripheral arterial disease (PAD), and determine if it improves walking ability.

Primary Outcome Measure

Carnosine for Peripheral Arterial Disease patients [ Time Frame: One year ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of LouisvilleLouisvilleKentucky40202
Shahid P Baba, Ph.D
[email protected]
502-852-4274
Amit J Dwivedi
[email protected]
5026450749

Find similar trials in Louisville, KY

By research site
University of Louisville· Louisville, KY

Related Studies